LAG3 in gastric cancer: it's complicated

J Cancer Res Clin Oncol. 2023 Sep;149(12):10797-10811. doi: 10.1007/s00432-023-04954-1. Epub 2023 Jun 14.

Abstract

Purpose: Lymphocyte activation gene 3 (LAG3) is thought to contribute to T cell exhaustion within the tumor microenvironment of solid tumors. This study aimed to analyze the spatial distribution of LAG3 + cells in relation to clinicopathological and survival data in a large set of 580 primary resected and neoadjuvantly treated gastric cancers (GC).

Methods: LAG3 expression was evaluated in tumor center and invasive margin using immunohistochemistry and whole-slide digital image analysis. Cases were divided into LAG3-low and LAG3-high expression groups based on (1) median LAG3 + cell density, (2) cut-off values adapted to cancer-specific survival using Cutoff Finder application.

Results: Significant differences in spatial distribution of LAG3 + cells were observed in primarily resected GC, but not in neoadjuvantly treated GC. LAG3 + cell density showed evident prognostic value at following cut-offs: in primarily resected GC, 21.45 cells/mm2 in tumor center (17.9 vs. 10.1 months, p = 0.008) and 208.50 cells/mm2 in invasive margin (33.8 vs. 14.7 months, p = 0.006); and in neoadjuvantly treated GC, 12.62 cells/mm2 (27.3 vs. 13.2 months, p = 0.003) and 123.00 cells/mm2 (28.0 vs. 22.4 months, p = 0.136), respectively. Significant associations were found between LAG3 + cell distribution patterns and various clinicopathological factors in both cohorts. In neoadjuvantly treated GC, LAG3 + immune cell density was found to be an independent prognostic factor of survival (HR = 0.312, 95% CI 0.162-0.599, p < 0.001).

Conclusion: In this study, a higher density of LAG3 + cells was associated with favorable prognosis. Current results support the need for extended analysis of LAG3. Differences in the distribution of LAG3 + cells should be considered, as they could influence clinical outcomes and treatment responses.

Keywords: Gastric cancer; Lymphocyte activation gene 3 protein; Prognosis; Tumor microenvironment; Tumor-infiltrating lymphocytes.

MeSH terms

  • Humans
  • Immunohistochemistry
  • Lymphocyte Activation Gene 3 Protein* / genetics
  • Lymphocyte Activation Gene 3 Protein* / metabolism
  • Lymphocytes, Tumor-Infiltrating
  • Prognosis
  • Stomach Neoplasms* / pathology
  • Tumor Microenvironment

Substances

  • Lag3 protein, human
  • Lymphocyte Activation Gene 3 Protein